Definium Therapeutics Inc. Common Shares vs NEOS S&P 500 High Income ETF — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B), while NEOS S&P 500 High Income ETF trades at $54.08 (market cap $12.50B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 2.7× Definium Therapeutics Inc. Common Shares's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| DFTX | SPYI | |
|---|---|---|
Market Cap | $4.71B | $12.50B |
Volume | 1,966,636 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $48.45 | $54.42 |
52-Week Low | $10.68 | $47.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $3.67B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →